IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT NO.: 5,935,946

First Page		Document Content
Date: 2007-12-21 07:53:28 Civil law Tenofovir Reexamination United States Patent and Trademark Office Claim Patent Reverse-transcriptase inhibitor Gilead Sciences Alkoxide United States patent law Chemistry Law		IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT NO.: 5,935,946 Add to Reading List Source URL: www.pubpat.org Download Document from Source Website File Size: 520,68 KB Share Document on Facebook

	AIDS InfoNetwww.aidsinfonet.org Fact Sheet Number 478 Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) DocID: 1ucKl - View Document
	67 Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared With Tenofovir disoproxil fumarate Wai-Kay Seto2, Yasuhiro Asahina3, Cheng-Yuan Peng4, Carol Stanciu5, Djamal Abdur DocID: 1timf - View Document
	ABSTRACT FINAL ID: LB-7 TITLE: Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naïve Caucasian patients DocID: 1sU8R - View Document
	Pre-Exposure Prophylaxis (PrEP): A primer for primary care providers Daily emtricitabine/tenofovir (Truvada®) is safe and effective for reducing the risk of HIV acquisition in sexually active men and women and injection DocID: 1rPaA - View Document
	PrEPARING FOR THE END OF HIV? How to access PrEP in Contra Costa County… For Insured Folks: Private Medical Provider-Most health insurance companies cover Truvada (emtricitabine and tenofovir disoproxil fumarate, the m DocID: 1rAVd - View Document